The Dutch pharmaceutical market is currently generating revenues of some 5.1 billion euros
. With this amount it represents one of the mid-sized national markets among EU-countries. Pharmaceutical expenditures are the second largest category among
, only topped by medical specialized care. Health care expenditures in the Netherlands total almost 52 billion euros (while by the broader definition – including long-term treatment, welfare, social services and child care – these costs are even twice as high).
In a phase of recovery
The Dutch health market in general saw a significant recovery in the volume of health goods already in the second pandemic year of 2021.
Expenditures in most of the main health segments were reported to have grown. As of 2023, pharmaceutical revenues in the Netherlands within basic health insurance coverage have exceeded five billion euros for the first time since 2011.
Independent pharmacies are top
Like in most countries, the Dutch pharmaceutical market is dominated by pharmacies as the major distribution channel.
In the Netherlands, the number of public pharmacies has been almost the same over the last five years, with only slight fluctuations. Most pharmacies in the country are independent, while around a third are owned by larger chains. As of 2023, of nearly two thousand pharmacies, 1,063 were independent. Average pharmacy costs per person under the Dutch Health Insurance Act came to 277 euros in 2021, significantly lower than in the years before 2012.
The consumer’s side
When it comes to the consumer side,
omeprazole was the third most used drug in the Netherlands during 2022. Some 1.23 million Dutch used the proton pump inhibitor (PPI) to treat symptoms of the gastroesophageal reflux disease. Based on expenditures, the leading drug in 2022 was anticoagulant apixaban, sold under the brand name Eliquis. In general, there is a decreasing trend in dispensed medicines among some major therapeutic classes in the Netherlands like, for example,
antidepressants, analgesics, and respiratory medicines.
The self-medication market in the Netherlands is substantial, generating revenues totaling around 912 million euros, with vitamins and minerals representing the largest single chunk, followed by respiratory products and pain relief remedies.
This text provides general information. Statista assumes no
liability for the information given being complete or correct.
Due to varying update cycles, statistics can display more up-to-date
data than referenced in the text.
